The product intended use is for ablation treatments of local, low and medium-risk prostate cancer with no lymph node and distant metastasis within T2 stage; and benign prostatic hyperplasia (BPH) that has caused urinary dysfunction (IPSS>13, PV<80ml, protrusion of middle lobe into bladder < 1 cm). It is not intended use for lesions located in the anterior tip of the prostate tissue and in front of the urethra, and other focal points cannot be reached or acoustic power blocked by organs. The product must be used by qualified and trained clinicians in medical institutions.
